MAY 2022LIFE SCIENCES REVIEW6The global clinical trial management system market size is poised to observe substantial growth during the forecast period, as governments are introducing supportive initiatives to promote clinical trials for various medicines and vaccines. Venture capitalists are seeing major opportunities for progress in the pharma sector and are increasing their investments in this regard.The COVID-19 pandemic was instrumental in boosting the installation of CTMS software as the demand for vaccines grew exponentially. As COVID-19 cases rose across regions, medical research organizations started conducting extensive research activities, augmenting the use of CTMS solutions.The North America clinical trial management system market may reach over $836.6 million in value by 2027. Investments made by the regional pharma companies in life sciences are growing every year. The organizations are striving to make groundbreaking drug discoveries, fostering the use of CTMS software. The support showcased by the governments to the pharma sector will positively impact the adoption of clinical trials. Updated CTMS software will help in understanding the customer's needs, thereby boosting their use in clinical trials.The regional industry value from CTMS services will witness 12.4 percent CAGR through 2027. CTMS providers can offer a variety of services, including site monitoring, clinical project management, payment services, quality assurance, and drug safety, among many others. This will help medicine producers get a clear idea about the status of their production and help them determine the safety of their product.The enterprise-based CTMS solutions will develop significantly as the healthcare infrastructure is improving with each technological innovation. The number of organizations participating in clinical trials is growing at a considerable pace to offer high-quality drugs for chronic illnesses. The digitalization of healthcare systems has been pivotal in introducing the concept of virtual clinical trials. Many healthcare companies are increasing their investments in drug discovery, which will strengthen the adoption of CTMS solutions. It can greatly increase the transparency of clinical trials and speed up the drug-making process.Let us know your thoughts.EDITORIALThe Emerging Importance of Clinical Trial ManagementCopyright © 2022 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com May - 09 - 2022, Vol 03, Issue - 06 Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasVisualizersRonald DonovanDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsSalesStephen Thomassales@lifesciencesreview.comVictor Cruz
< Page 5 | Page 7 >